Literature DB >> 12173802

Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty.

Jayanti Nerurkar1, William E Wade, Bradley C Martin.   

Abstract

STUDY
OBJECTIVE: To compare the cost-effectiveness of warfarin or enoxaparin with no prophylaxis for prevention of venous thromboembolism in patients undergoing total knee replacement (TKR) or knee arthroplasty.
DESIGN: Literature search and retrospective database analysis. PATIENTS: Cohort of 42,692 patients over 40 years old who underwent TKR or knee arthroplasty, with a subsequent length of stay of at least 1 day, and who did not die postoperatively.
MEASUREMENTS AND MAIN RESULTS: Both warfarin and enoxaparin were superior to no prophylaxis with regard to costs and clinical outcomes. Enoxaparin was associated with medical charges of $26,455/patient and prevented 194 deaths/10,000 patients. Warfarin was associated with medical charges of $27,360/patient and prevented 124 deaths/10,000 patients.
CONCLUSIONS: A wide range of model estimates and assumptions identify enoxaparin as the prophylaxis modality of choice for preventing venous thromboembolism and subsequent clinical complications following total knee replacement surgery.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12173802     DOI: 10.1592/phco.22.12.990.33609

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  8 in total

1.  Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

Authors:  Laura McCullagh; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

2.  Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China.

Authors:  Xiaoyu Yan; Xiaohua Gu; Lei Zhou; Houweng Lin; Bin Wu
Journal:  Clin Drug Investig       Date:  2016-12       Impact factor: 2.859

Review 3.  Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.

Authors:  Alok Kapoor; Warren Chuang; Nila Radhakrishnan; Kenneth J Smith; Dan Berlowitz; Jodi B Segal; Jeffrey N Katz; Elena Losina
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.

Authors:  Laura McCullagh; Lesley Tilson; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

5.  A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting.

Authors:  Sonja Zindel; Stephanie Stock; Dirk Müller; Björn Stollenwerk
Journal:  BMC Health Serv Res       Date:  2012-07-09       Impact factor: 2.655

Review 6.  Economic analyses of venous thromboembolism prevention strategies in hospitalized patients: a systematic review.

Authors:  Subarna Thirugnanam; Ruxandra Pinto; Deborah J Cook; William H Geerts; Robert A Fowler
Journal:  Crit Care       Date:  2012-03-09       Impact factor: 9.097

7.  Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.

Authors:  Xiaoyu Yan; Xiaohua Gu; Zhenxing Xu; Houweng Lin; Bin Wu
Journal:  Adv Ther       Date:  2016-12-20       Impact factor: 3.845

Review 8.  The potential benefits of low-molecular-weight heparins in cancer patients.

Authors:  Francisco Robert
Journal:  J Hematol Oncol       Date:  2010-01-14       Impact factor: 17.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.